Cover Image
市場調查報告書

腦膜瘤:開發中產品分析

Meningioma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361621
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
腦膜瘤:開發中產品分析 Meningioma - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 71 Pages
簡介

本報告提供腦膜瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦膜瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腦膜瘤:企業開發中的治療藥

腦膜瘤:大學/機關研究中的治療藥

腦膜瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腦膜瘤:企業開發中的產品

腦膜瘤:大學/機關研究中的產品

腦膜瘤的治療藥開發企業

  • Arno Therapeutics, Inc.
  • Boehringer Ingelheim GmbH
  • e-Therapeutics Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Progenics Pharmaceuticals, Inc.

腦膜瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦膜瘤:最近的開發平台趨勢

腦膜瘤:暫停中的計劃

腦膜瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9390IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H1 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.

A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningioma - Overview
    • Meningioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Meningioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Meningioma - Companies Involved in Therapeutics Development
    • Arno Therapeutics Inc
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline Plc
    • Novartis AG
    • Pharma Mar SA
    • Progenics Pharmaceuticals Inc
  • Meningioma - Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-42 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Edotreotide Labeled Yttrium 90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HXR-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabectedin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vistusertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Meningioma - Dormant Projects
  • Meningioma - Discontinued Products
  • Meningioma - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma
      • Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe
      • Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Meningioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Meningioma - Pipeline by Arno Therapeutics Inc, H1 2017
  • Meningioma - Pipeline by AstraZeneca Plc, H1 2017
  • Meningioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Meningioma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Meningioma - Pipeline by Novartis AG, H1 2017
  • Meningioma - Pipeline by Pharma Mar SA, H1 2017
  • Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Meningioma - Dormant Projects, H1 2017
  • Meningioma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Meningioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top